Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase Ib study (NCT03248479) of magrolimab, an anti-CD47 antibody, in combination with azacitidine in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). In this interview, Dr Daver focuses on the safety and efficacy data from the AML cohort. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).